Evicenter
Biktarvy (bictegravir, emtricitabine, and tenofovir alafenamide) in HIV-1 infection
Manufacturer
Gilead Sciences, Inc.
Prescribing information
Biktarvy (opens in a new tab)
Questions
57
Last updated

All questions

Safety: Biktarvy (bictegravir, emtricitabine, and tenofovir alafenamide) in HIV-1 infection

10 questions · 5 sources

Side effects

What are the most common side effects of Biktarvy?

Note: Each row of Table 1 lists values in header order: BIKTARVY and ABC/DTG/3TC (Trial 1489), then BIKTARVY and DTG + FTC/TAF (Trial 1490).

What side effects were reported after switching to Biktarvy?

Note: On the page, the Study 1878 columns share the Study 1844 row labels; its values are listed in the order Headache, Flatulence, Nausea, Diarrhea, BIKTARVY then comparator.

Does Biktarvy cause weight gain?

Note: The weight data in the linked PDF cite Sax et al., Clin Infect Dis 2021, which the virologically suppressed page lists as the Study 4030 publication.

What are the long-term side effects of Biktarvy?

Note: Study 1489 data cover Weeks 0 to 240 for adults randomized to Biktarvy and Weeks 144 to 240 for adults who switched from ABC/DTG/3TC to Biktarvy at Week 144. The page lists the Study 1490 values without row labels, so they are not quoted here.

Monitoring

Does Biktarvy raise serum creatinine?

Safety

Can Biktarvy cause kidney problems?

What happens after a Biktarvy overdose?

What is the Biktarvy boxed warning about hepatitis B after stopping treatment?

What are the warnings and precautions for Biktarvy?

“Drug interactions: See Contraindications and Drug Interactions sections. Consider the potential for drug interactions prior to and during BIKTARVY therapy and monitor for adverse reactions. Immune reconstitution syndrome, including the occurrence of autoimmune disorders with variable time to onset, has been reported. New onset or worsening renal impairment: Postmarketing cases of renal impairment, including acute renal failure, proximal renal tubulopathy (PRT), and Fanconi syndrome have been reported with tenofovir alafenamide (TAF)–containing products. Do not initiate BIKTARVY in patients with estimated creatinine clearance (CrCl) <30 mL/min except in virologically suppressed adults <15 mL/min who are receiving chronic hemodialysis. Patients with impaired renal function and/or taking nephrotoxic agents (including NSAIDs) are at increased risk of renal-related adverse reactions. Discontinue BIKTARVY in patients who develop clinically significant decreases in renal function or evidence of Fanconi syndrome. Renal monitoring: Prior to or when initiating BIKTARVY and during therapy, assess serum creatinine, CrCl, urine glucose, and urine protein in all patients as clinically appropriate. In patients with chronic kidney disease, assess serum phosphorus. Lactic acidosis and severe hepatomegaly with steatosis: Fatal cases have been reported with the use of nucleoside analogs, including FTC and TDF. Discontinue BIKTARVY if clinical or laboratory findings suggestive of lactic acidosis or pronounced hepatotoxicity develop, including hepatomegaly and steatosis in the absence of marked transaminase elevations.” (opens the source at this quote in a new tab)

What are the contraindications for Biktarvy?